Xihong Lin

Xihong Lin

Auto-generated profile, based on publicly available information

Xihong Lin

Harvard University

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MWMichael C. Wu
Michael C. Wu
SLSeunggeun Lee
Seunggeun Lee
TCTianxi Cai
Tianxi Cai
YLYun Li
Yun Li
MBMichael Boehnke
Michael Boehnke
XLXihong Lin
Xihong Lin

19 May 2020 in JAMA
Verified
Journal Article
Open access
PDF file
APAn Pan
An Pan
LLLi Liu
Li Liu
CWChaolong Wang
Chaolong Wang
HGHuan Guo
Huan Guo
XHXingjie Hao
Xingjie Hao
TWTangchun Wu
Tangchun Wu
Coronavirus disease 2019 (COVID-19) is an emerging respiratory infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first detected in early December 2019 in Wuhan, China. As of April 6, 2020, COVID-19 had quickly spread to the majority of countries worldwide, affected more than 1.1 million individuals, and caused nearly 63 000 deaths.1 Although studies have described the clinical characteristics of patients with COVID-19,2-7 and a previous study has reported the early transmission dynamics of the first 425 confirmed cases in Wuhan,8 more recent data are required to illustrate the full spectrum of the epidemiological characteristics of the outbreak in the epicenter.

1 August 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SLSeunggeun Lee
Seunggeun Lee
MEMary J. Emond
Mary J. Emond
MBMichael J. Bamshad
Michael J. Bamshad
KBKathleen C. Barnes
Kathleen C. Barnes
MRMark J. Rieder
Mark J. Rieder
XLXihong Lin
Xihong Lin

1 July 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SLSeunggeun Lee
Seunggeun Lee
GAGonçalo R. Abecasis
Gonçalo R. Abecasis
MBMichael Boehnke
Michael Boehnke
XLXihong Lin
Xihong Lin

15 September 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
IDIttai Dayan
Ittai Dayan
HRHolger Roth
Holger Roth
AZAoxiao Zhong
Aoxiao Zhong
AHAhmed Harouni
Ahmed Harouni
AGAmilcare Gentili
Amilcare Gentili
QLQuanzheng Li
Quanzheng Li

14 June 2012 in Biostatistics
Verified
Journal Article
Open access
PDF file
SLSeunggeun Lee
Seunggeun Lee
MWMichael C. Wu
Michael C. Wu
XLXihong Lin
Xihong Lin
With development of massively parallel sequencing technologies, there is a substantial need for developing powerful rare variant association tests. Common approaches include burden and non-burden tests. Burden tests assume all rare variants in the target region have effects on the phenotype in the same direction and of similar magnitude. The recently proposed sequence kernel association test (SKAT) (Wu, M. C., and others, 2011. Rare-variant association testing for sequencing data with the SKAT. The American Journal of Human Genetics89, 82–93], an extension of the C-alpha test (Neale, B. M., and others, 2011. Testing for an unusual distribution of rare variants. PLoS Genetics7, 161–165], provides a robust test that is particularly powerful in the presence of protective and deleterious variants and null variants, but is less powerful than burden tests when a large number of variants in a region are causal and in the same direction. As the underlying biological mechanisms are unknown in practice and vary from one gene to another across the genome, it is of substantial practical interest to develop a test that is optimal for both scenarios. In this paper, we propose a class of tests that include burden tests and SKAT as special cases, and derive an optimal test within this class that maximizes power. We show that this optimal test outperforms burden tests and SKAT in a wide range of scenarios. The results are illustrated using simulation studies and triglyceride data from the Dallas Heart Study. In addition, we have derived sample size/power calculation formula for SKAT with a new family of kernels to facilitate designing new sequence association studies.